Evidence map›Paper›PMID 41858899›Full record

ArticleiScience2026

Gut microbiome disparities reflect type 2 diabetes progression and medication status.

Manoj Kumar, Samradhi Singh, Raj Ojha, Mona Kriti, Gwoncheol Park, Vinod Verma, Namrata Pal, Poonam Sharma, Swasti Shubham, Megha K Pandey and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Manoj KumarNational Institute for Research in Environmental Health, Indian Council for Medical Research, Bhopal 462030, Madhya Pradesh, India.
Samradhi SinghNational Institute for Research in Environmental Health, Indian Council for Medical Research, Bhopal 462030, Madhya Pradesh, India.
Raj OjhaNational Institute for Research in Environmental Health, Indian Council for Medical Research, Bhopal 462030, Madhya Pradesh, India.
Mona KritiNational Institute for Research in Environmental Health, Indian Council for Medical Research, Bhopal 462030, Madhya Pradesh, India.
Gwoncheol ParkThe Gut Biome Lab, Florida State University, Tallahassee, FL 32306, USA.
Vinod VermaStem Cell Research Centre, Department of Hematology, Sanjay Gandhi Post-Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh 226014, India.
Namrata PalNational Institute for Research in Environmental Health, Indian Council for Medical Research, Bhopal 462030, Madhya Pradesh, India.
Poonam SharmaNational Institute for Research in Environmental Health, Indian Council for Medical Research, Bhopal 462030, Madhya Pradesh, India.
Swasti ShubhamNational Institute for Research in Environmental Health, Indian Council for Medical Research, Bhopal 462030, Madhya Pradesh, India.
Megha K PandeyTranslational Medicine Center, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh 462020, India.
Devraj J ParasannanavarDivision of Clinical Epidemiology, Indian Council for Medical Research-National Institute of Nutrition, Hyderabad 500007, India.
Devojit K SarmaNational Institute for Research in Environmental Health, Indian Council for Medical Research, Bhopal 462030, Madhya Pradesh, India.
Rajnarayan R TiwariNational Institute for Research in Environmental Health, Indian Council for Medical Research, Bhopal 462030, Madhya Pradesh, India.
Ravinder NagpalThe Gut Biome Lab, Florida State University, Tallahassee, FL 32306, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 2 diabetes mellitus (T2D) prevalence is rapidly increasing in India, yet microbiome signatures linked to disease progression and oral antidiabetic therapy remain underexplored. We performed full-length 16S rRNA sequencing of fecal samples from prediabetics (PDs), untreated newly diagnosed T2D (UKT2D), and clinically diagnosed T2D patients (KT2D), alongside biochemical, anthropometric, and medication data. Despite comparable glycemic control and insulin resistance between UKT2D and KT2D groups, gut microbial diversity was significantly reduced in KT2D, coinciding with antidiabetic drug use, primarily metformin.

Indexed as

endocrinologymicrobiomepublic health

Identifiers

PMID41858899
PMCPMC12997337

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.